Palatin completes enrollment in Phase 2 study of bremelanotide in obesity

Palatin (PTN) has completed enrollment in the study investigating the safety, tolerability, and effectiveness of co-administration of bremelanotide with tirzepatide for the treatment of obesity. All patients in the study are expected to have completed all dosing and patient visits by the end of January 2025, with topline data readout expected before the end of March 2025. The primary endpoint of the BMT-801 trial is to demonstrate the safety and increased efficacy of co-administration of bremelanotide with tirzepatide on reducing body weight.